HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | IGF-1R ↓ ↑ | Insulin Receptor ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMS-536924 |
++
IGF-1R, IC50: 100 nM |
+++
Insulin Receptor, IC50: 73 nM |
FAK,MEK | 98% | |||||||||||||||
| GSK1904529A |
+++
IGF-1R, IC50: 27 nM |
+++
Insulin Receptor, IC50: 25 nM |
98+% | ||||||||||||||||
| Picropodophyllin |
++++
IGF-1R, IC50: 1 nM |
99%+ | |||||||||||||||||
| NVP-AEW541 |
++
IGF-1R, IC50: 0.15 μM |
++
Insulin Receptor, IC50: 0.14 μM |
FLT3 | 99%+ | |||||||||||||||
| NVP-ADW742 |
+
IGF-1R, IC50: 0.17 μM |
98% | |||||||||||||||||
| GSK1838705A |
+++
IGF-1R, IC50: 2 nM |
++++
Insulin Receptor, IC50: 1.6 nM |
ALK | 98% | |||||||||||||||
| BMS-754807 |
++++
IGF-1R, IC50: 1.8 nM |
++++
Insulin Receptor, IC50: 1.7 nM |
99%+ | ||||||||||||||||
| Linsitinib |
+++
IGF-1R, IC50: 35 nM |
++
Insulin Receptor, IC50: 75 nM |
99%+ | ||||||||||||||||
| AG1024 |
+
IGF-1R, IC50: 7 μM |
+
Insulin Receptor, IC50: 57 μM |
98% | ||||||||||||||||
| PQ401 |
+
IGF-1R, IC50: <1 μM |
99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | NF-κB ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ammonium pyrrolidine-1-carbodithioate | ✔ | 98% | |||||||||||||||||
| QNZ |
++++
NF-κB, IC50: 11 nM |
99%+ | |||||||||||||||||
| Sodium 4-Aminosalicylate Dihydrate | ✔ | 98% | |||||||||||||||||
| Sodium Salicylate | ✔ | 95% | |||||||||||||||||
| Parthenolide | ✔ | p53 | 97% HPLC | ||||||||||||||||
| JSH-23 |
+
NF-κB, IC50: 7.1 μM |
98% | |||||||||||||||||
| Phenethyl caffeate | ✔ | 98% | |||||||||||||||||
| Andrographolide | ✔ | 98+% | |||||||||||||||||
| Curcumin | ✔ | Nrf2,HDAC | 98% | ||||||||||||||||
| SC75741 |
+++
NF-κB, EC50: 200 nM |
99%+ | |||||||||||||||||
| CBL0137 HCl |
++
NF-κB, EC50: 0.47 μM |
p53 | 99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | COX ↓ ↑ | COX-1 ↓ ↑ | COX-2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piroxicam | ✔ | 98% | |||||||||||||||||
| Salicylic acid | ✔ | 98% | |||||||||||||||||
| Phenacetin | ✔ | 98% | |||||||||||||||||
| Etodolac | ✔ | 99% | |||||||||||||||||
| Flunixin meglumine | ✔ | 98% | |||||||||||||||||
| Ibuprofen L-lysine | ✔ | 98% | |||||||||||||||||
| Nabumetone | ✔ | 98% | |||||||||||||||||
| Acemetacin | ✔ | 98% | |||||||||||||||||
| Diflunisal | ✔ | 98% | |||||||||||||||||
| Pranoprofen | ✔ | 98% | |||||||||||||||||
| Ampiroxicam | ✔ | 98% | |||||||||||||||||
| Meloxicam | ✔ | 98% | |||||||||||||||||
| Sulindac | ✔ | 98% | |||||||||||||||||
| Ketoprofen | ✔ | 98% | |||||||||||||||||
| Mefenamic Acid | ✔ | 95% | |||||||||||||||||
| Bromfenac sodium | ✔ | 98% | |||||||||||||||||
| Oxaprozin | ✔ | 99% | |||||||||||||||||
| Aspirin | ✔ | 99% | |||||||||||||||||
| Nepafenac | ✔ | 98% | |||||||||||||||||
| Zaltoprofen | ✔ | 99% | |||||||||||||||||
| Salicin | ✔ | 98% | |||||||||||||||||
| Suprofen | ✔ | 99%+ | |||||||||||||||||
| Xanthohumol | ✔ | 99% | |||||||||||||||||
| Parecoxib | ✔ | 98% | |||||||||||||||||
| Tolfenamic Acid |
+++
COX-2, IC50: 0.2 μM |
98% | |||||||||||||||||
| Etoricoxib | ✔ | 99% | |||||||||||||||||
| Niflumic Acid | ✔ | 98% | |||||||||||||||||
| Valdecoxib |
++++
COX-2, IC50: 5 nM |
99+% | |||||||||||||||||
| Ibuprofen |
+
COX-1, IC50: 13 μM |
+
COX-2, IC50: 370 μM |
98% | ||||||||||||||||
| Indomethacin |
++
COX1, IC50: 0.28 μM |
+
COX-2, IC50: 14 μM |
97% | ||||||||||||||||
| Lornoxicam |
++++
COX-1, IC50: 5 nM |
++++
COX-2, IC50: 8 nM |
98% | ||||||||||||||||
| Meclofenamic acid sodium |
++++
COX-1, IC50: 40 nM |
+++
COX-2, IC50: 50 nM |
99% | ||||||||||||||||
| Asaraldehyde | ✔ | 98% | |||||||||||||||||
| Naproxen |
+
COX-1, IC50: 8.7 μM |
+
COX-2, IC50: 5.2 μM |
98% | ||||||||||||||||
| Diclofenac Sodium Salt |
+++
COX-1, IC50: 60 nM |
+++
COX-2, IC50: 200 nM |
98% | ||||||||||||||||
| NS-398 |
++
COX-2, IC50: 3.8 μM |
95% | |||||||||||||||||
| Amfenac Sodium Hydrate |
++
COX-1, IC50: 250 nM |
+++
COX-2, IC50: 150 nM |
98%+ | ||||||||||||||||
| Nimesulide |
+
COX-2, IC50: 26 μM |
98% | |||||||||||||||||
| Lumiracoxib |
++
COX-1, Ki: 3 μM |
+++
COX-2, Ki: 60 nM |
98% | ||||||||||||||||
| Rutaecarpine | ✔ | 95% | |||||||||||||||||
| Celecoxib |
++++
COX-2, IC50: 40 nM |
98% | |||||||||||||||||
| Carprofen |
++++
canine COX2, IC50: 30 nM |
98% | |||||||||||||||||
| Ketorolac |
++
COX-1 (human), IC50: 1.23 μM |
++
COX-2 (human), IC50: 3.50 μM |
98% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Ginsenoside Rg5 is a natural product isolated and purified from the roots of Panax ginseng C. A. Mey. showing anti-inflammatory effect. |
| Concentration | Treated Time | Description | References | |
| HEK293T cells | 300 nM | 24 hours | Increased interaction between MyoD and E2A | J Ginseng Res. 2023 Nov;47(6):726-734 |
| conventional type 1 dendritic cells (cDC1s) | 50 μM | 2 hours | Enhanced efferocytosis of cDC1s from SLC7A11-WT mice | J Ginseng Res. 2023 Nov;47(6):784-794 |
| bone marrow-derived dendritic cells (BMDCs) | 50 μM | 48 hours | Enhanced efferocytotic capability of BMDCs from db/db mice | J Ginseng Res. 2023 Nov;47(6):784-794 |
| SK-N-SH cells | 10 μM | 48 hours | To evaluate the inhibitory effect of ginsenoside Rg5 on HSV-1-induced neuroinflammation, results showed that ginsenoside Rg5 significantly inhibited inflammatory cytokine expression. | J Ginseng Res. 2024 Jul;48(4):384-394 |
| Vero cells | 10 μM | 48 hours | To evaluate the inhibitory effect of ginsenoside Rg5 on HSV-1 replication, results showed that ginsenoside Rg5 significantly inhibited HSV-1 replication. | J Ginseng Res. 2024 Jul;48(4):384-394 |
| primary pulmonary microvascular endothelial cells (PPMECs) | 20 μM and 60 μM | 6 hours | Ginsenoside Rg5 pretreatment significantly reduced IR-induced oxidative stress, apoptosis, and mitochondrial dysfunction. | J Ginseng Res. 2025 May;49(3):260-270 |
| H9c2 cells | 10 μM | 2 hours | Rg5 promoted HK-II binding to mitochondria and inhibited Drp1 activation via Akt activation, protecting mitochondrial morphological and functional integrity. | Cell Death Dis. 2017 Feb 23;8(2):e2625 |
| Neonatal rat ventricular myocytes (NRVMs) | 10 μM | 2 hours | Rg5 prevented cellular acidification by combating fatty-acid oxidation and restoring PDH activity, thereby protecting mitochondrial HK-II binding and enhancing cardiomyocyte resistance to ischemic injury. | Cell Death Dis. 2017 Feb 23;8(2):e2625 |
| Primary myoblast cells | 300 nM | 72 hours | Promoted primary myoblast differentiation, increased number of fused myoblasts | J Ginseng Res. 2023 Nov;47(6):726-734 |
| C2C12 myoblasts | 100,300 nM | 48 hours | Promoted C2C12 myoblast differentiation, increased expression levels of MHC, troponin-T, and myogenin | J Ginseng Res. 2023 Nov;47(6):726-734 |
| Caco-2 cells | 8 μM | 2 hours | To evaluate the effects of Rg5 on the function of ABCB1 transporter, results showed that Rg5 inhibited the function of ABCB1 transporter. | J Ginseng Res. 2020 Mar;44(2):247-257 |
| A549/T cells | 2, 4, 8 μM | 48 hours | To evaluate the reversal effects of Rg5 on ABCB1-mediated multidrug resistance, results showed that Rg5 significantly increased the intracellular accumulation of ABCB1 substrates, thereby reversing drug resistance. | J Ginseng Res. 2020 Mar;44(2):247-257 |
| A2780/T cells | 2, 4, 8 μM | 48 hours | To evaluate the reversal effects of Rg5 on ABCB1-mediated multidrug resistance, results showed that Rg5 significantly increased the intracellular accumulation of ABCB1 substrates, thereby reversing drug resistance. | J Ginseng Res. 2020 Mar;44(2):247-257 |
| NCI-H292 human pulmonary mucoepidermoid carcinoma cells | 0, 10, 50, 100 μg/mL | 2 hours | To evaluate the effect of Rg5 on MUC5AC secretion and mRNA levels. Results showed that Rg5 significantly reduced MUC5AC secretion and mRNA levels without cytotoxicity. | J Ginseng Res. 2023 Jan;47(1):97-105 |
| HT22 cells | 0 mg/mL, 20 mg/mL, 40 mg/mL | 4 h pretreatment followed by 6 h thermal stress | Investigate the protective effect of Rg5 against thermal stress-induced apoptosis in HT22 cells. Results showed Rg5 inhibited p21 expression and PARP cleavage, reduced NO production, and modulated HO-1/Nrf2 signaling and cognitive-associated proteins (e.g., BDNF, GSK3β). | J Ginseng Res. 2018 Apr;42(2):225-228 |
| Administration | Dosage | Frequency | Description | References | ||
| ICR mice | Isoproterenol-induced cardiac ischemia model | Oral | 50 mg/kg | 2 consecutive days | Rg5 promoted Akt translocation to mitochondria, increased mitochondrial HK-II binding, suppressed Drp1 recruitment, and reduced cell apoptosis, thereby protecting the heart from ischemic injury. | Cell Death Dis. 2017 Feb 23;8(2):e2625 |
| Nude mice | A549/T cell xenograft model | Intraperitoneal injection | 10, 30, 50 mg/kg | Every 3 days for a total of nine injections | To evaluate the reversal effects of Rg5 on ABCB1-mediated multidrug resistance in vivo, results showed that Rg5 significantly suppressed the growth of drug-resistant tumors. | J Ginseng Res. 2020 Mar;44(2):247-257 |
| Mice | Db/db mice (diabetic model) | Oral gavage | 20 or 80 mg/kg/day | Once daily for one week | Promoted skin wound healing in diabetic mice and reduced apoptotic cells in wound areas | J Ginseng Res. 2023 Nov;47(6):784-794 |
| Zebrafish | Zebrafish model | Water bath exposure | 2.54 mg/mL | 24 hours | To study the metabolic pathways and metabolites of ginsenoside Rg5 in zebrafish | J Ginseng Res. 2017 Jan;41(1):78-84 |
| C57BL/6 mice | Radiation-induced acute lung injury model | Intraperitoneal injection | 30 mg/kg/day | For 3 consecutive days | Ginsenoside Rg5 pretreatment attenuated radiation-induced acute lung damage, preserved endothelial cell junction integrity, and maintained endothelial barrier function in vivo. | J Ginseng Res. 2025 May;49(3):260-270 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.30mL 0.26mL 0.13mL |
6.52mL 1.30mL 0.65mL |
13.04mL 2.61mL 1.30mL |
|
| CAS号 | 186763-78-0 |
| 分子式 | C42H70O12 |
| 分子量 | 767.0 |
| SMILES Code | C[C@@]([C@@]12C)(CC[C@@]3([H])C4(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@@H](/C(C)=C/C/C=C(C)\C)CC2)([H])[C@]3(CC[C@@H]4O[C@@](O[C@H](CO)[C@@H](O)[C@@H]5O)([H])[C@@H]5O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)C |
| MDL No. | MFCD22200429 |
| 别名 | 人参皂苷Rg5 |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 50 mg/mL(65.19 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1